Human tumor antigens recognized by T cells and their implications for cancer immunotherapy

Ryo Ueda, Tomonori Yaguchi, Yutaka Kawakami

研究成果: Chapter

抜粋

Recent clinical trials of immunotherapies indicate that tumor reactive autologous T cells are able to regress even advanced, large tumors in melanoma patients. For example, the adoptive transfer of CD8+ cytotoxic T lymphocytes (CTL) specifically targeted for identified tumor antigens following lymphodepletive treatment, such as fludarabine/cyclophosphamide administration and total body irradiation, led to objective tumor responses in more than 70% of patients with melanoma (Dudley et al. 2008). Immunological analyses on these tumor tissues demonstrated that administered T cells may eliminate tumor cells through direct killing and cytokine secretion. Therefore, CD8+ CTLs that recognize MHC class I positive cancer cells are important for in vivo tumor rejection.

元の言語English
ホスト出版物のタイトルInnate Immune Regulation and Cancer Immunotherapy
出版者Springer New York
ページ335-345
ページ数11
ISBN(印刷物)9781441999146, 9781441999139
DOI
出版物ステータスPublished - 2012 1 1

ASJC Scopus subject areas

  • Medicine(all)

フィンガープリント Human tumor antigens recognized by T cells and their implications for cancer immunotherapy' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Ueda, R., Yaguchi, T., & Kawakami, Y. (2012). Human tumor antigens recognized by T cells and their implications for cancer immunotherapy. : Innate Immune Regulation and Cancer Immunotherapy (pp. 335-345). Springer New York. https://doi.org/10.1007/9781441999146_19